Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 6/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24423697 | 1.00 | TLR8 (0.33) | TLR8TLR7TLR9TBK1CHEK1 | |
| SCHEMBL24423699 | 1.00 | TLR8 (0.33) | TLR8TLR7TLR9TBK1CHEK1 | |
| SCHEMBL29585018 | 1.00 | TLR8 (0.33) | TLR8TLR7TLR9TBK1CHEK1 | |
| SCHEMBL24423698 | 1.00 | TLR8 (0.33) | TLR8TLR7TLR9TBK1CHEK1 | |
| SCHEMBL24423911 | 0.91 | FFAR4 (0.37) | TLR8TLR7TLR9TBK1KDM5A | |
| SCHEMBL29584891 | 0.91 | FFAR4 (0.37) | TLR8TLR7TLR9TBK1KDM5A | |
| SCHEMBL24424524 | 0.91 | FFAR4 (0.37) | TLR8TLR7TLR9TBK1KDM5A | |
| SCHEMBL24423469 | 0.91 | PDCD1 (0.31) | PDCD1CD274KDM4E | |
| SCHEMBL24424523 | 0.91 | FFAR4 (0.37) | TLR8TLR7TLR9TBK1KDM5A | |
| SCHEMBL29585040 | 0.91 | FFAR4 (0.37) | TLR8TLR7TLR9TBK1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | TLR8 3046/4885TLR7 1640/4885TLR9 2630/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | TLR8 1704/4885TLR7 829/4885TLR9 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.